Vogenx Inc (NASDAQ:VOGX) Shares Shorted: Short Interest Up 93.6% in October

Vogenx Inc (NASDAQ:VOGX) was the recipient of a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 74,122 shares, an increase of 93.6% from the October 15th total of 38,289 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily trading volume, of 80,725 shares, the short-interest ratio is currently 0.9 days.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. JonesTrading began coverage on Vogenx in a report on Tuesday, September 1st. They issued a “buy” rating and a $55.00 price objective for the company. WBB Securities assumed coverage on shares of Vogenx in a report on Wednesday, September 2nd. They set a “speculative buy” rating and a $42.00 target price on the stock. Weiss Ratings started coverage on shares of Vogenx in a report on Monday, November 9th. They set a “sell (e-)” rating on the stock. Zacks Research raised shares of Vogenx to a “hold” rating in a research report on Monday, September 28th. Finally, Wall Street Zen lowered shares of Vogenx from a “hold” rating to a “sell” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $48.50.

Vogenx Stock Down 13.0%

NASDAQ:VOGX traded down $2.48 during trading hours on Friday, reaching $16.67. The company’s stock had a trading volume of 94,312 shares, compared to its average volume of 98,963. The stock has a market cap of $247.55 million and a P/E ratio of -79.38. Vogenx has a 12 month low of $12.95 and a 12 month high of $38.41. The firm has a 50 day simple moving average of $22.03.

Vogenx (NASDAQ:VOGX) last posted its earnings results on Friday, November 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. On average, analysts expect that Vogenx will post -0.61 EPS for the current fiscal year.

About Vogenx

Vogenx Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc. is based in RALEIGH, NC.